| Ytd | -0.45% | |
| 1y | -22.05% |
| Open | 11.51 | Prev Close | 11.43 | Low | 11.10 | High | 11.75 | Mkt Cap | 56.64M |
| Vol | 7.33K | Avg Vol | 17.52K | EPS | -2.37 | P/E | N/A | Forward P/E | -1.17 |
| Beta | 0.48 | Short Ratio | 1.10 | Inst. Own | 2.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 11.25 | 200-d Avg | 11.41 | 1yr Est | 6.50 |
INKT News
MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript
MiNK Therapeutics NASDAQ: INKT said it initiated dosing in a randomized Phase II trial of its alloge
MiNK Therapeutics (NASDAQ:INKT) held its second-quarter earnings conference call on Thursday. Below
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.62) per share which missed the anal
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage
MiNK advances agenT-797 across respiratory, oncology and immune disease studies while expanding its
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage
First patient dosed marks rapid transition from trial activation to active treatment in patients wit
NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (NASDAQ: INKT), a cli
MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company developing allogen
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage
HC Wainwright & Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:INKT) with a Bu
MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript
MiNK Therapeutics NASDAQ: INKT said it is advancing its off-the-shelf invariant natural killer T cel
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.57) per share which beat the analys
Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distres
MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iN
NEW YORK and LVIV, Ukraine, May 14, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage bio
iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cance
iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cance
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage
MiNK Therapeutics, Inc. (NASDAQ: INKT - Get Free Report) has received a consensus rating of "Hold" f
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stag
NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stag
MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stag
Domo Inc (DOMO) stock jumped 48.8% in pre-market trading after beating Q4 earnings expectations by 1
